about
Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluationPrehospital noninvasive ventilation for acute respiratory failure: systematic review, network meta-analysis, and individual patient data meta-analysisPre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluationExtrapolating Survival from Randomized Trials Using External Data: A Review of MethodsWhat is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.Systematic review, network meta-analysis and exploratory cost-effectiveness model of randomized trials of minimally invasive techniques versus surgery for varicose veins.Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.Complementary and Alternative Medicine for Management of Premature Ejaculation: A Systematic Review.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis.How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression.Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group PerspectiveDegarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Assurance calculations for planning clinical trials with time-to-event outcomes.A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis.A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology AppraisalR and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case StudyHow Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness
P50
Q26822253-4D82E990-710A-4677-AFB8-EC0A5CA149DFQ26995651-5049C851-7B8A-4695-875F-29B5C2F77AC1Q27022399-C6C2B9BC-7E4D-496C-A865-5866200F3AECQ33654108-D7894AA0-3978-4E59-ABA1-64C3A4074FD4Q35169339-A8B3F51E-9B3F-4A14-871B-D108D77D8892Q35194914-48C8A0DC-B9C1-40B5-8522-16AE76D7CA41Q36028384-DE9F1BA9-A4A1-45E7-94AC-3490245A5857Q37636075-A1AE3A04-6A26-4942-85D5-62FC3AE2755BQ38149091-0A1D2583-86FF-4CB4-851A-6CA3EB635887Q38610119-D03470AC-BAE2-4423-8AA4-12AF93FAD6F5Q38673414-FC364066-21BB-40E0-B6E2-E3855FB36B27Q38687870-86E4CBAC-6716-4723-9F85-A5B091F8A212Q38835685-B3B4981C-A2C6-4EB9-8E6C-7DC6D3A3AD82Q38923237-5393D3DC-AAE7-4FFE-88A9-9D6ED6585BB9Q39036192-AA4EC838-A359-480F-9960-618465A08BB3Q42000169-5A0F69FB-439E-4669-9514-60E39A89F069Q48108552-F397AD16-57EB-43DA-BF29-64079495162EQ50215048-5DA97B6A-31AD-4706-A474-6969F26F8AD4Q54123254-6B395EA7-9095-4375-BD8B-C4645F1413ADQ90470980-9F5170EF-8E50-49ED-968A-7B1839D2F0E0Q90822933-588424EC-1CF5-4C3A-96CB-20FFF3B0283EQ91423373-AE2039A9-2486-4FD4-A6C3-F7D03A57161F
P50
description
researcher ORCID ID = 0000-0003-3568-7124
@en
wetenschapper
@nl
name
Shijie Ren
@af
Shijie Ren
@an
Shijie Ren
@ast
Shijie Ren
@ay
Shijie Ren
@az
Shijie Ren
@br
Shijie Ren
@ca
Shijie Ren
@ce
Shijie Ren
@ceb
Shijie Ren
@co
type
label
Shijie Ren
@af
Shijie Ren
@an
Shijie Ren
@ast
Shijie Ren
@ay
Shijie Ren
@az
Shijie Ren
@br
Shijie Ren
@ca
Shijie Ren
@ce
Shijie Ren
@ceb
Shijie Ren
@co
prefLabel
Shijie Ren
@af
Shijie Ren
@an
Shijie Ren
@ast
Shijie Ren
@ay
Shijie Ren
@az
Shijie Ren
@br
Shijie Ren
@ca
Shijie Ren
@ce
Shijie Ren
@ceb
Shijie Ren
@co
P106
P1153
55910895500
P31
P496
0000-0003-3568-7124